Literature DB >> 7756675

Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes.

J Bertram1, K Palfner, M Killian, W Brysch, K H Schlingensiepen, W Hiddemann, M Kneba.   

Abstract

In the present study we investigated the effectiveness of 14, 15 and 18 nucleotide antisense phosphorothioate oligonucleotides (S-ODNs) directed to four different regions of the published mdr-1 gene sequence to reduce the level of mdr-1 gene product (p170, P-glycoprotein) and its function in the over-expressing cell lines Lo-VoDxR, S180DxR and KBChR8-5. The highest efficiency in reduction of multiple drug resistance was obtained at a concentration of 2 microM. In proliferation assays a growth reduction of 50% was observed after exposure of doxorubicin-resistant cells to S-ODN3. p170 protein expression of the resistant cell line LoVoDxR was reduced to the level of the sensitive cell line LoVo as shown by Western blot analysis. S-ODN3 reduced the ID50 of the two human cell lines up to 60% (LoVoDxR) and 21% (KBChR8-5), respectively, but showed no effect in the murine cell line S180DxR. In contrast, S-ODN1 was most effective in the murine system (67% reduction of the ID50), less effective in LoVoDxR (34%) and exhibited no effect in cell line KBChR8-5. Based on the results with the antisense oligonucleotides, a ribozyme directed against the mRNA target region of S-ODN3 was designed. This ribozyme was able to reduce the mdr-1 mRNA in total RNA preparations from cell line LoVoDxR up to 80% after an incubation time of 6 h in the presence of 10 mM MgCl2 at pH 7.5. A modified ribozyme was investigated in cell culture and reduced chemo-resistance of the resistant cell line LoVoDxR and ex vivo cultured blasts of acute myeloid leukemia patients up to 50%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756675     DOI: 10.1097/00001813-199502000-00015

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  5 in total

Review 1.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.

Authors:  C Daly; S Coyle; S McBride; L O'Driscoll; N Daly; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

3.  Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).

Authors:  Milica Pesić; Tijana Andjelković; Jasna Banković; Ivanka D Marković; Ljubisa Rakić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2008-05-21       Impact factor: 3.850

4.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.